NuVasive launches next generation biologics technology

NuVasive Inc. announced the U.S. launch of its AttraX Putty.

AttraX Putty, which reportedly has been used globally since 2011 and received FDA 510(k) clearance in 2015, is a synthetic, osteoconductive bone-void filler used for the repair of bone defects. Featuring a unique biotextured surface, AttraX Putty is designed to help drive regeneration of bone at the implanted site.

“We are excited to officially launch AttraX Putty for surgical use in the [United States] U.S. and expect it to be a cornerstone of our expanding biologics portfolio,” Pat Miles, president and chief operating officer at NuVasive, said in a press release. “AttraX Putty has helped improve outcomes for more than 20,000 spine patients worldwide, and we are pleased to now bring this biologic to market in the United States. Today’s launch is another example of NuVasive’s continued commitment to invest in industry-leading innovation that deliver the best possible patient outcomes.”

 

Reference:

www.nuvasive.com

NuVasive Inc. announced the U.S. launch of its AttraX Putty.

AttraX Putty, which reportedly has been used globally since 2011 and received FDA 510(k) clearance in 2015, is a synthetic, osteoconductive bone-void filler used for the repair of bone defects. Featuring a unique biotextured surface, AttraX Putty is designed to help drive regeneration of bone at the implanted site.

“We are excited to officially launch AttraX Putty for surgical use in the [United States] U.S. and expect it to be a cornerstone of our expanding biologics portfolio,” Pat Miles, president and chief operating officer at NuVasive, said in a press release. “AttraX Putty has helped improve outcomes for more than 20,000 spine patients worldwide, and we are pleased to now bring this biologic to market in the United States. Today’s launch is another example of NuVasive’s continued commitment to invest in industry-leading innovation that deliver the best possible patient outcomes.”

 

Reference:

www.nuvasive.com